Results 81 to 90 of about 24,385 (265)

Demystifying fungal systematics: A gateway to fungal literacy and societal/ecological relevance through familiar species

PLANTS, PEOPLE, PLANET, EarlyView.
Fungal systematics can feel overwhelming given the vast species diversity within this kingdom, with numerous subgroups at every taxonomic rank. This often creates a disconnect between the undertsnidng of fungal taxonomic diversity and their societal relevance.
Anna Vaiana, Francis Martin, Rasmus Kjøller, Toby Spribille, Garima Singh   +4 more
wiley   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Limited Sampling Strategy for the Estimation of Mycophenolic Acid and its Acyl Glucuronide Metabolite Area under the Concentration-Time Curve in Japanese Lung Transplant Recipients

Journal of Pharmacy & Pharmaceutical Sciences, 2019
Purpose: The dose of mycophenolate mofetil (MMF) used to prevent rejection after lung transplantation is often adjusted based on the 12-hour area under the concentration-time curve (AUC0-12) of mycophenolic acid (MPA).
Masaki Tanaka, Masafumi Kikuchi, Shinya Takasaki, Tensei Hirasawa, Kensuke Sigeta, Aoi Noda, Miki Akiba, Yasushi Matsuda, Hisashi Oishi, Tetsu Sado, Masafumi Noda, Yoshinori Okada, Nariyasu Mano, Hiroaki Yamaguchi   +13 more
doaj   +1 more source

Adaptive evolution of drug targets in producer and non-producer organisms [PDF]

, 2012
Mycophenolic acid (MPA) is an immunosuppressive drug produced by several fungi in Penicillium subgenus Penicillium. This toxic metabolite is an inhibitor of IMP dehydrogenase (IMPDH). The MPA biosynthetic cluster of P.
Balzarini, Bentley, Bjarne G. Hansen, Chooi, Christian S. Kaas, Collart, Farazi, Frisvad, Frisvad, Gao, Geu-Flores, Hansen, Hansen, Hans J. Genee, Hartman, Hedstrom, Hoff, Jakob B. Nielsen, Jenks, Jens C. Frisvad, Khersonsky, Kohler, Kohler, Lightfoot, Link, Lizbeth Hedstrom, MacPherson, Nimmesgern, Norholm, O'Brien, Regueira, Saitou, Sintchak, Tracewell, Uffe H. Mortensen, van den Berg, Wang, Wilson, Wilson, Wu, Xin E. Sun   +40 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes [PDF]

, 2010
OBJECTIVE This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing β-cells in subjects with new-onset type 1 diabetes.
Gottlieb, Peter A., Greenbaum, Carla J., Krause-Steinrauf, Heidi, Lachin, John M., Moran, Antoinette M., Quinlan, Scott, Rodriguez, Henry, Schatz, Desmond A., Skyler, Jay S., Type 1 Diabetes TrialNet MMF/DZB Study Group, Wilson, Darrell M.   +10 more
core   +2 more sources

A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell‐derived islets for the treatment of type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims To explore UK key‐opinion leader perspectives on the future role of stem cell‐derived islets (sc‐islets) in islet transplantation for people with type 1 diabetes (T1D). Methods Four UK‐based key‐opinion leaders evaluated current limitations of donor islet transplantation and reviewed emerging evidence, clinical pathways and logistical ...
Thomas Strakosch, Shareen Forbes
wiley   +1 more source

The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation

Transplant Infectious Disease, EarlyView.
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam, Abdinoor Abdi, Wyatt Tarter, Ben Langworthy, Adam Bregman, Karam M. Obeid   +5 more
wiley   +1 more source

PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION

Фармакоэкономика, 2015
Objective: to calculate cost difference between two approaches for immunosuppressive therapy after renal transplantation: everolimus plus reducedexposure cyclosporine and mycophenolic acid plus standard-exposure cyclosporine. Methods.
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach   +3 more
doaj   +1 more source

Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. [PDF]

, 2009
International audienceBACKGROUND: Mycophenolate mofetil, a prodrug of mycophenolic acid (MPA), is used during non-myeloablative and reduced-intensity conditioning haematopoetic stem cell transplantation (HCT) to improve engraftment and reduce graft ...
Debord, Jean, Deconinck, Eric, Kantelip, Jean-Pierre, Larosa, Fabrice, Legrand, Faezeh, Marquet, Pierre, Royer, Bernard, Saint-Marcoux, Franck   +7 more
core   +3 more sources